New combo therapy aims to control prostate cancer without castration

NCT ID NCT06084338

Recruiting now Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a combination of targeted radiation (SBRT) and a radioactive drug called Pluvicto can control metastatic castration-resistant prostate cancer without the need for ongoing hormone therapy. Sixty participants will stop castration and receive the treatments, with half also getting testosterone gel. The main goal is to see if the cancer stays under control for at least 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pluvicto (Lu177-PSMA) and stereotactic ablative radiotherapy
What this could lead to: If successful, this could offer a way to control metastatic prostate cancer without long-term hormone therapy, potentially improving quality of life.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply broadly. The combination therapy also carries risks like radiation side effects and toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Edward Hines Jr. VA Hospital, Hines, IL
RECRUITING

Hines, Illinois, 60141-3030, United States
Richard L. Roudebush VA Medical Center, Indianapolis, IN
RECRUITING

Indianapolis, Indiana, 46202-2884, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITING

Ann Arbor, Michigan, 48105-2303, United States
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
RECRUITING

West Los Angeles, California, 90073-1003, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.